Swiss National Bank Buys 900 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Amelie Mason 2021-02-24 09:02

[embedded content]

NeoGenomics logo Swiss National Bank raised its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 0.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 237,200 shares of the medical research company’s stock after buying an additional 900 shares during the period. Swiss National Bank’s holdings in NeoGenomics were worth $12,771,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in NEO. Envestnet Asset Management Inc. increased its holdings in NeoGenomics by 8.3% during the third quarter. Envestnet Asset Management Inc. now owns 53,771 shares of the medical research company’s stock valued at $1,984,000 after buying an additional 4,125 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in NeoGenomics by 177.8% during the third quarter. Nisa Investment Advisors LLC now owns 3,750 shares of the medical research company’s stock valued at $138,000 after buying an additional 2,400 shares during the last quarter. MAI Capital Management purchased a new stake in shares of NeoGenomics in the third quarter worth $517,000. Howland Capital Management LLC increased its stake in shares of NeoGenomics by 32.9% in the third quarter. Howland Capital Management LLC now owns 41,653 shares of the medical research company’s stock worth $1,537,000 after purchasing an additional 10,316 shares in the last quarter. Finally, Fiduciary Planning LLC purchased a new stake in shares of NeoGenomics in the third quarter worth $41,000. 91.06% of the stock is owned by institutional investors and hedge funds.

Get NeoGenomics alerts:

NEO has been the subject of a number of analyst reports. SVB Leerink increased their price objective on shares of NeoGenomics from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Friday, January 8th. Truist initiated coverage on shares of NeoGenomics in a research note on Wednesday, January 27th. They issued a “buy” rating and a $65.00 price objective for the company. BTIG Research initiated coverage on shares of NeoGenomics in a research note on Friday, December 11th. They issued a “buy” rating for the company. Benchmark increased their price objective on shares of NeoGenomics from $40.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Finally, Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, February 11th. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. NeoGenomics currently has an average rating of “Buy” and an average target price of $43.58.

In other NeoGenomics news, VP Jennifer Balliet sold 15,000 shares of the stock in a transaction on Friday, December 11th. The shares were sold at an average price of $49.99, for a total transaction of $749,850.00. Following the completion of the transaction, the vice president now owns 39,980 shares in the company, valued at $1,998,600.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Bonello sold 8,000 shares of the stock in a transaction on Wednesday, December 2nd. The shares were sold at an average price of $46.80, for a total transaction of $374,400.00. Following the transaction, the insider now owns 20,060 shares of the company’s stock, valued at approximately $938,808. The disclosure for this sale can be found here. Insiders have sold 242,883 shares of company stock valued at $11,946,734 in the last quarter. 6.50% of the stock is owned by company insiders.

NEO stock opened at $52.99 on Wednesday. NeoGenomics, Inc. has a 52 week low of $20.47 and a 52 week high of $61.57. The company has a quick ratio of 6.22, a current ratio of 6.54 and a debt-to-equity ratio of 0.25. The company has a fifty day simple moving average of $55.01 and a two-hundred day simple moving average of $45.74. The firm has a market capitalization of $5.88 billion, a P/E ratio of -1,765.74 and a beta of 0.79.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.